Stock ORY ORYZON GENOMICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Market Closed - BME
Other stock markets
 11:35:26 2024-04-26 am EDT 		5-day change 1st Jan Change
2 EUR +0.91% Intraday chart for Oryzon Genomics S.A. +5.60% +5.93%
Apr. 22 Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat CI
Apr. 08 ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer CI

Evolution of the average Target Price on Oryzon Genomics S.A.

Price target over the last 5 years

History of analyst recommendation changes

a026920615603e2e43b2294.FhsFlXTM6SOd9fqIFHuO404j3jk7WtdXL5xM7KM2Mhw.Uy599gy60WT7o5C_RCHvixdAtlZfI7UaGPIrpsUPUEh7VVTAJIm_UKm3nQ~816a2985e261672d712e85c010fc297c

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2 EUR
Average target price
6.676 EUR
Spread / Average Target
+233.82%
High Price Target
12 EUR
Spread / Highest target
+500.00%
Low Price Target
2.5 EUR
Spread / Lowest Target
+25.00%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ORY Stock
  4. Consensus Oryzon Genomics S.A.